Health and Fitness Health and Fitness
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009

Optigenex Inc.: Optigenex Inc. Announces Rollout of Activar(R) AC-11(R) Oral Supplements and Activar(R) AC-11(R) Next Generatio


//health-fitness.news-articles.net/content/2009/ .. ements-and-activar-r-ac-11-r-next-generatio.html
Published in Health and Fitness on Tuesday, July 28th 2009 at 6:13 GMT, Last Modified on 2009-07-28 06:13:40 by Market Wire   Print publication without navigation


NEW YORK, NY--(Marketwire - July 28, 2009) - Optigenex Inc. (PINKSHEETS: [ OPGX ]) announced today its partner Ekson Farma is prepared to launch its family of AC-11® oral supplements and skin care products under the brand name Activar® for distribution throughout the major pharmacies in Turkey. Under an exclusive license signed in early 2008, Ekson has invested significant capital, resources and time in determining market acceptance of Optigenex's patented technology and has also devoted considerable efforts towards clinical and scientific research to broaden the market applications for its unique anti-aging products. The agreement and subsequent commercialization by Ekson sets the stage for the introduction of AC-11® to educated and health-conscious Turkish consumers and represents another important strategic initiative in the company's plans to establish AC-11® as a recognized international brand.

All-natural, and standardized at a minimum of 8 per cent Carboxy Alkyl Esters ("CAEs™"), AC-11® is the only patented aqueous extract of the Uncaria species that can make the following therapeutic claims ("DNA repair, Immune enhancement and Inhibition of pro-inflammatory agents") which are validated by a broad spectrum of scientific and clinical studies.

AC-11® already has gained a major foothold in Japan and has been introduced in other select territories of Asia as a branded ingredient used by over 100 manufacturers and distributors in a variety of anti-aging cosmetic, cosmeceutical and dietary supplement products. With their regional alliance together, Optigenex and Middle Eastern based Ekson Farma anticipate similar market penetration, growth and expansion for AC-11®

Daniel Zwiren, president and CEO of Optigenex Inc., said, "We are delighted to have a company with the scientific pedigree and reputation of Ekson Farma as part of our growing list of marketing and distribution partners. Moreover, we believe the unique scientific properties of AC-11® along with Ekson's research will allow us to grow our business rapidly in this key geographic region."

Doctor Yaman Er, president of Ekson Farma, added, "We are very pleased with the reception AC-11® has received and attribute this attention to the key differentiators of AC-11® supported by clinical and scientific studies. Those studies validate the efficacy of this all-natural ingredient, which is harvested in the Amazon Rainforest and manufactured by Centroflora Group Botucatu, Brazil. Consumer demand in our market is driven by new and result-oriented technologies. We believe our alliance with Optigenex provides us with the opportunity to introduce Turkey and the Middle East to the next major brand in oral and topical applications."

About Ekson Farma:

Ekson Farma: Founded in 1994, Ekson Farma is an applied sciences and marketing company focused on providing wellness solutions and related technologies to physicians, pharmacies and the general medical community. Ekson's strategy is to select superior and innovative products validated by clinical and scientific studies, establish consumer and physician acceptance through test marketing and ultimately distribute those products with the goal of improving the quality of life for health conscious consumers and patients. Ekson through its collaboration with research partner OKSANTE LABORATORIES is noted for its development of diagnostic tools utilizing DNA sequencing and molecular diagnostics with an emphasis on early detection of disease and DNA mutations.

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound, as it core product. AC-11® is a bioactive, water-soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email or call the company at: [ dzwiren@optigenex.com ] 201 355 2098.

* The statements made in this press release have not been evaluated by the Food and Drug Administration. The products mentioned in this release are not intended to diagnose, treat, cure or prevent any disease.


Publication Contributing Sources

Similar Health and Fitness Publications